ASAQ to treat malaria = Fixed dose combination of Artesunate + Amodiaquine
  • Launched in 2007
  • The concrete results of an innovative partnership between DNDi and Sanofi
  • Meets the latest WHO guidelines for malaria treatment in Africa
  • Simple regimen: 1 or 2 tablets once a day for 3 days
  • Available at only 0.5$ for children, 1$ for adults
  • Meets the highest standard of quality
  • Made in the South for use in the South: ASAQ is produced in Morocco
  • Available under the name Artesunate-Amodiaquine Winthrop (ASAQ) for public market and Coarsucam for private market
  • Handed over to the MMV Access and Product Management team in May 2015 to help maximize patient access – read statement

ASAQ Press Pack, March 1st 2007


Read more about:
The Successful Development of a Fixed Dose Combination of ASAQ

The ASAQ Story


Key Scientific Publications

BMC Medicine, March 2015
The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data

Malaria Journal, December 2014
Fixed dose artesunate amodiaquine – a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine

Malaria Journal, March 2014
Plasmodium falciparum clearance in clinical studies of artesunate-amodiaquine and comparator treatments in sub-Saharan Africa, 1999–2009

Malaria Journal, July 2013
Efficacy of ASAQ and AL fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial 

Malaria Journal, July 2013
Tolerability and safety of ASAQ and AL fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia

Malaria Journal, July 2009
Randomized, multicentre assessment of the efficacy and safety of ASAQ – a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria

Implementation progress

Handed over to MMV Access team

More than 437 million treatments distributed

ASAQ registered in 35 countries & territories

Technology transfer to African industry partner ongoing